Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: Results from phase III TRIBE trial by the gruppo oncologico del nord ovest

Annals of Oncology

Volumn 26, Issue 6, 2015, Pages 1188-1194

  Cremolini, C ^a,b   Loupakis, F ^a,b   Antoniotti, C ^a,b   Lonardi, S ^c   Masi, G ^a,b   Salvatore, L ^a,b   Cortesi, E ^d   Tomasello, G ^e   Spadi, R ^f   Zaniboni, A ^g   Tonini, G ^h   Barone, C ⁱ   Vitello, S ^j   Longarini, R ^k   Bonetti, A ^l   D'Amico, M ^m   Di Donato, S ⁿ   Granetto, C ^o   Boni, L ⁿ   Falcone, Alfredo ^a,b  

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e CREMONA HOSPITAL   (Italy)

^f Azienda Ospedaliero Universitaria Città Della Salute e Della Scienza   (India)

^g Fondazione Poliambulanza   (Italy)

^h UNIVERSITY CAMPUS BIO MEDICO   (Italy)

ⁱ CATHOLIC UNIVERSITY   (Italy)

^j Neurology Unit   (Italy)

^k SAN GERARDO HOSPITAL   (Italy)

^l Mater Salutis Hospital   (Italy)

^m GALLIERA HOSPITAL   (Italy)

ⁿ ISTITUTO TOSCANO TUMORI   (Italy)

^o S CROCE E CARLE HOSPITAL   (Italy)

more..

Author keywords

Bevacizumab; Depth of response; Early tumor shrinkage; FOLFOXIRI

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; PLATINUM COMPLEX;

ARTICLE; CANCER INHIBITION; CANCER PROGNOSIS; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DEPTH OF RESPONSE; DRUG EFFICACY; EARLY TUMOR SHRINKAGE; HUMAN; MAJOR CLINICAL STUDY; METASTATIC COLORECTAL CANCER; MULTICENTER STUDY; ONCOLOGICAL PARAMETERS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; POST PROGRESSION SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL; SURVIVAL TIME; TREATMENT RESPONSE; ADULT; AGED; ANALOGS AND DERIVATIVES; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; COLORECTAL NEOPLASMS; COMPARATIVE STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG EFFECTS; ITALY; KAPLAN MEIER METHOD; METASTASIS; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME; TUMOR VOLUME;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CAMPTOTHECIN; CHI-SQUARE DISTRIBUTION; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FLUOROURACIL; HUMANS; ITALY; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84938086499     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdv112     Document Type: Article

References (13)

1. Folprecht G, Grothey A, Alberts S et al. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol 2005; 16:1311-1319.
2. Buyse M, Thirion P, Carlson RW et al. Relation between tumour response to firstline chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer. Lancet 2000; 356:373-378.
3. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
4. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-247.
5. Piessevaux H, Buyse M, Schlichting M et al. Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab. J Clin Oncol 2013; 31:3764-3775.
6. Douillard J-Y, Siena S, Tabernero J et al. Overall survival (OS) and tumor shrinkage outcomes in patients with symptomatic/asymptomatic metastatic colorectal cancer (mCRC): data from the PRIME study. Ann Oncol 2013; 24 (suppl 4): iv32-iv33.
7. Mansmann UR, Sartorius U, Laudender RP et al. Deepness of response: a quantitative analysis of its impact on post-progression survival time after first-line treatment in patients with mCRC. J Clin Oncol 2013; 31(suppl 4): abstr 427.
8. Loupakis F, Cremolini C, Masi G et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med 2014; 371:1609-1618.
9. Contal C, O'Quigley J. An application of changepoint methods in studying the effect of age on survival in breast cancer. Comput Stat Data Anal 1999; 30:253-270.
10. Pencina MJ, D'Agostino RB. Overall C as a measure of discrimination in survival analysis: model specific population value and confidence interval estimation. Stat Med 2004; 23:2109-2123.
11. Stintzing S, Modest D, Von Weikersthal LF et al. Independent radiological evaluation of objective response, early tumor shrinkage, and depth of response in FIRE-3 (AIO KRK-0306) in the final RAS evaluable population. Ann Oncol 2014; 25(suppl 5): LBA11.
12. Sommeijer D, Shi Q, Saad ED et al. Early predictors of prolonged overall survival (OS) in patients (pts) on first-line chemotherapy (CT) for metastatic colorectal cancer (mCRC): an ARCAD study with individual patient data (IPD) on 10,962 pts. J Clin Oncol 2014; 32(suppl 5): abstr 3538.
13. Rivera F, Karthaus M, Hecht R et al. First-line treatment with modified FOLFOX6 (mFOLFOX6) + panitumumab (pmab) or bevacizumab (bev) in wild-type (WT) RAS metastatic colorectal carcinoma (mCRC): tumor response outcomes beyond RECIST. J Clin Oncol 2015; 33(suppl 3): abstr 660.